ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/PDGFR-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/PDGFR-inhibitor
9
trial(s) found.
NCT05678673
Advanced
Phase 3
Recruiting
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (
STELLAR-304
)
KIT inhibitor,first generation
MET/VEGFR2/AXL/MER inhibitor
PDGFR inhibitor
VEGFR inhibitor
anti-PD-1 monoclonal antibody
Non-clear cell renal cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Border Medical Oncology Research Unit
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4032 - Chermside - The Prince Charles Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT05245968
Advanced
Phase 1
Recruiting
A Phase 1 Study of TAS-116 (Pimitespib) in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumor
BCR-ABL1 inhibitor,first generation
HSP90 inhibitor
KIT inhibitor
PDGFRA inhibitor
Gastrointestinal stromal tumour
VIC
3004 - Melbourne, Southbank - Alfred Health
SA
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research
NCT04625907
Radonc
Phase 1 / Phase 2
Recruiting
FaR-RMS
: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Cyclophosphamide
Dactinomycin
Doxorubicin
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
Ifosfamide
Irinotecan
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
PDGFR inhibitor
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
VEGFR inhibitor
Vincristine
Vinorelbine
alkylating agent
anthracycline
antineoplastic antibiotic
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cytotoxic chemotherapy
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
topoisomerase inhibitor
vinca alkaloid
+ KIT/PDGFR/RET/VEGFR/FGFR inhibitor
Rhabdomyosarcoma
NSW
2031 - Randwick - Sydney Children's Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Children's Hospital at Westmead
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04164199
Advanced
Phase 3
Enrolling by invitation
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies (
BGB-A317-290-LTE1
)
PARP inhibitor
anti-PD-1 monoclonal antibody
+ KIT/PDGFR/RET/VEGFR inhibitor
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03970447
Radonc
Phase 2 / Phase 3
Recruiting
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (
GBM-AGILE
)
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
Lomustine
PDGFR inhibitor
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Pegargiminase
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
Troriluzole
VAL-083
VEGFR inhibitor
alkylating agent
arginine deiminase-polyethylene glycol conjugate
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
glutamate modulator
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
+ KIT/PDGFR/RET/VEGFR/FGFR inhibitor
Glioblastoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12624000532505
Radonc
Phase 3
Recruiting
International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1 (
INTER-EWING-1
)
Cyclophosphamide
Doxorubicin
Etoposide
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
Ifosfamide
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
PDGFR inhibitor
RET inhibitor
Radiotherapy
Regorafenib
VEGFR inhibitor
Vincristine
Vinorelbine
alkylating agent
anthracycline
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cytotoxic chemotherapy
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
topoisomerase inhibitor
vinca alkaloid
+ KIT/PDGFR/RET/VEGFR/FGFR inhibitor
Ewing sarcoma
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12619001655134
Haem
Phase 2
Recruiting
AMLM25: An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (
INTERVENE
) Acute Myeloid Leukaemia
Bcl2 inhibitor
+ PDGFR inhibitor
Acute myeloid leukaemia
NCT05805501
Advanced
Phase 2
paused
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (
BO43936
)
KIT inhibitor,ATP-competitive
VEGFR/PDGFR inhibitor
Clear cell renal cell carcinoma
QLD
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (6)
Enrolling by invitation (1)
paused (1)
Status unknown (1)
Recruitment Country and State
NSW (5)
QLD (5)
VIC (5)
SA (4)
NZ (2)
WA (2)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (1)
Phase 2 (2)
Phase 2 / Phase 3 (1)
Phase 3 (3)
Trial Type
Advanced (5)
Radonc (3)
Haem (1)
Cancer Therapy Class
KIT
100%
PDGFR
100%
VEGFR
89%
RET
44%
PD-1
33%
PD-1/PD-L1
33%
VEGFR2
33%
FGFR
33%
FGFR1
33%
FGFR1/2/3
33%
FGFR2
33%
FGFR3
33%
FGFR4
33%
MET
22%
BCR-ABL1
22%
PDGFRA
22%
LAG3
22%
TIGIT
22%
PI3K
22%
mTOR
22%
mTORC1
22%
mTORC2
22%
FLT3
22%
AXL
11%
MER
11%
HSP90
11%
ERBB2
11%
HPK1
11%
OX40
11%
PARP
11%
VEGF
11%
VEGFR1
11%
VEGFR3
11%
PI3K delta
11%
PI3Kalpha
11%
Bcl2
11%
HDAC
11%
PKC
11%
ALK
11%
ATR
11%
CDK4
11%
CDK6
11%
CRAF
11%
EGFR
11%
JAK1
11%
JAK2
11%
RAF
11%
ROS1
11%
SMO
11%
SRC
11%
YES1
11%
Facility
2050 - Camperdown - Chris O'Brien Lifehouse (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
2109 - North Ryde - Macquarie University Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
4032 - Chermside - The Prince Charles Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research (1)
2031 - Randwick - Sydney Children's Hospital (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
3168 - Clayton - Monash Children's Hospital (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
6009 - Perth - Perth Children's Hospital (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2031 - Randwick - Prince of Wales Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
Cancer Type
Cancer
Solid tumour
Kidney cancer
Urogenital cancer
Sarcoma
Non-clear cell renal cell carcinoma
Gastrointestinal cancer
Gastrointestinal stromal tumour
Upper gastrointestinal cancer
Rhabdomyosarcoma
Soft tissue sarcoma
Central nervous system cancer
Glioblastoma
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
Bone cancer
Ewing family of tumours
Ewing sarcoma
Primitive neuroectodermal tumour
Acute myeloid leukaemia
Haematological malignancy
Leukaemia
Myeloid leukaemia
Clear cell renal cell carcinoma
Head and neck cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy